Literature DB >> 8145042

Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.

T van der Poll1, M Levi, C E Hack, H ten Cate, S J van Deventer, A J Eerenberg, E R de Groot, J Jansen, H Gallati, H R Büller.   

Abstract

The role of interleukin 6 (IL-6) in the toxic sequelae of sepsis is controversial. To assess the part of IL-6 in inflammatory responses to endotoxin, we investigated eight chimpanzees after either a bolus intravenous injection of Escherichia coli endotoxin (n = 4; 4 ng/kg) or after the same dose of endotoxin with a simultaneous bolus intravenous injection of an anti-IL-6 mAb (30 mg; n = 4). Anti-IL-6 did not affect the induction of the cytokine network (tumor necrosis factor [TNF], soluble TNF receptors types I and II, and IL-8) by endotoxin, nor did it influence the occurrence of a neutrophilic leukocytosis and neutrophil degranulation, as monitored by the measurement of elastase-alpha 1-antitrypsin complexes. In contrast, anti-IL-6 markedly attenuated endotoxin-induced activation of coagulation, monitored with the plasma levels of the prothrombin fragment F1+2 and thrombin-antithrombin III complexes, whereas activation of fibrinolysis, determined with the plasma concentrations of plasmin-alpha 2-antiplasmin complexes, remained unaltered. We conclude that IL-6 does not have a feedback effect on the release of other cytokines after injection of endotoxin, and that it is not involved in endotoxin-induced neutrophilia or neutrophil degranulation. IL-6 is, however, an important intermediate factor in activation of coagulation in low grade endotoxemia in chimpanzees.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145042      PMCID: PMC2191443          DOI: 10.1084/jem.179.4.1253

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

Review 1.  Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response.

Authors:  J M Le; J Vilcek
Journal:  Lab Invest       Date:  1989-12       Impact factor: 5.662

2.  In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs.

Authors:  T R Ulich; J del Castillo; K Z Guo
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells.

Authors:  J M Thompson; J R Gralow; R Levy; R A Miller
Journal:  Cytometry       Date:  1985-09

Review 4.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

5.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

Authors:  D Aderka; J M Le; J Vilcek
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

6.  Activation of neutrophils by recombinant interleukin 6.

Authors:  L Borish; R Rosenbaum; L Albury; S Clark
Journal:  Cell Immunol       Date:  1989-07       Impact factor: 4.868

7.  Functional discrimination between interleukin 6 and interleukin 1.

Authors:  M Helle; L Boeije; L A Aarden
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

8.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

Authors:  R Schindler; J Mancilla; S Endres; R Ghorbani; S C Clark; C A Dinarello
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

9.  Increased plasma levels of interleukin-6 in sepsis.

Authors:  C E Hack; E R De Groot; R J Felt-Bersma; J H Nuijens; R J Strack Van Schijndel; A J Eerenberg-Belmer; L G Thijs; L A Aarden
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

10.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  69 in total

Review 1.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

2.  Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models.

Authors:  Javier Corral; José Yélamos; David Hernández-Espinosa; Yolanda Monreal; Ruben Mota; Isabel Arcas; Antonia Miñano; Pascual Parrilla; Vicente Vicente
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 3.  Tumour necrosis factor and Crohn's disease.

Authors:  S J Van Deventer
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

4.  High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Francesca Gotsch; Jawed Fareed; Debra Hoppensteadt; Nandor Gabor Than; Bo Hyun Yoon; Sam Edwin; Zhong Dong; Jimmy Espinoza; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-01

Review 5.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 6.  The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.

Authors:  Karen M Hook; Charles S Abrams
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

7.  Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats.

Authors:  H Jin; R Yang; S Marsters; A Ashkenazi; S Bunting; M N Marra; R W Scott; J B Baker
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.

Authors:  Offer Erez; Roberto Romer; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Ricardo Gomez; Eli Maymon; Percy Pacora; Samuel S Edwin; Chong Jai Kim; Nandor Gabor Than; Pooja Mittal; Lami Yeo; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

9.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

10.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.